• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

111.67 -2.50 (-2.19%)
Streaming Delayed Price Updated: 12:41 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
July 19, 2023
Results of The CAREgiver Burden in BBS (CARE-BBS) study show multifaceted burden of hyperphagia 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
July 17, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
July 13, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals's Return On Capital Employed Overview ↗
May 08, 2023
 
Via Benzinga
News headline image
A Preview Of Rhythm Pharmaceuticals's Earnings ↗
May 01, 2023
 
Via Benzinga
News headline image
What Will Amgen Buy Next? ↗
June 29, 2023
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
June 17, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 06, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Rhythm Pharmaceuticals ↗
March 02, 2023
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
May 22, 2023
Exclusive commercialization agreement allows physicians in Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman and Bahrain to prescribe IMCIVREE 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
May 08, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 05, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
May 02, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
April 24, 2023
IMCIVREE is eligible for federal reimbursement by Statutory Health Insurances in Germany 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
April 18, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
April 06, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
March 27, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 06, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
March 01, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
February 27, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
February 21, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
January 23, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Breakout Growth Stocks to Buy for the Long Haul ↗
January 09, 2023
These three have had big-time share gains backed up by breakthrough science. 
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 05, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
20 Favorite Biotech & Medical Stocks For 2023 ↗
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 07, 2022
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap